1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Analysis & Statistics in Japan, May 2019

Mental Health Analysis & Statistics in Japan, May 2019

1-30 of about 100 reports

Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • December 2018

SummaryKyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines.The company offers ethical drugs including ...

  • Industries : Pharmaceutical
  • Countries : United States, Japan
Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • Industry report
  • November 2018

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and OthersSummaryGlobalData’s new report, Japan Neurology Devices ...

  • Industries : Health Services, Healthcare, Patient Monitoring, Medical Device, Mental Health, Pathology
  • Countries : Japan, East Asia
Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • Company report
  • October 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018SummaryAccording ...

  • Industries : Pathology, Pharmaceutical, Therapy, Medical Biotechnology, Biopharmaceutical, Biopharmaceutical
  • Countries : Japan, Brazil, World, United States, Canada
Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027

  • $ 3995
  • Industry report
  • July 2018

Amyotrophic Lateral Sclerosis: Epidemiology Forecast to 2027SummaryAmyotrophic Lateral Sclerosis (ALS) is often referred to as "Lou Gehrig’s Disease" after the famous baseball player who was diagnosed ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, World, Germany, United Kingdom
Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

  • $ 10995
  • Industry report
  • July 2018

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027SummaryAmyotrophic Lateral Sclerosis (ALS) drug sales in 2017 were approximately $187M across the seven major markets - the US, 5EU ...

  • Industries : Therapy, Mental Health, Pharmaceutical, Pathology
  • Countries : United States, World, Japan
Restless Legs Syndrome - Pipeline Review, H2 2018

Restless Legs Syndrome - Pipeline Review, H2 2018

  • $ 2000
  • Company report
  • July 2018

Restless Legs Syndrome - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Pipeline Review, H2 2018, provides ...

  • Industries : Mental Health, Pathology, Pharmaceutical
  • Countries : United States, World, Japan
Parkinson’s Disease: Epidemiology Forecast to 2026

Parkinson’s Disease: Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • May 2018

Parkinson’s Disease: Epidemiology Forecast to 2026SummaryParkinson’s disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, ...

  • Industries : Mental Health, Pathology
  • Countries : United States, United Kingdom, Japan, Spain, Germany
Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • May 2018

Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026SummaryParkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% ...

  • Industries : Mental Health, Pathology
  • Countries : United States, World, Japan, North America
Trigeminal Neuralgia Drug Development- Pipeline Analysis Report

Trigeminal Neuralgia Drug Development- Pipeline Analysis Report

  • $ 999
  • Industry report
  • April 2018

Trigeminal neuralgia is one of the most painful clinical conditions causing sudden, intense, recurrent pain usually on one side of face supplied with trigeminal nerve. It affects around 65 to 275 thousand ...

  • Industries : Therapy, Pharmaceutical, Mental Health, Health Services, Pathology
  • Countries : United States, World, Japan
Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H1 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H1 2018

  • $ 3500
  • Company report
  • April 2018

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H1 2018SummaryAccording ...

  • Industries : Pathology, Pharmaceutical, Therapy
  • Countries : Brazil, World, Japan
Abilify/Abilify Maintena

Abilify/Abilify Maintena

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Drug Overview: Zyprexa

Drug Overview: Zyprexa

  • $ 10000
  • Industry report
  • April 2018

Drug OverviewZyprexa (Eli Lilly) contains the atypical antipsychotic olanzapine, which acts as an antagonist at the D2 and 5-HT2A receptors. Zyprexa was initially launched in September 1996 for the treatment ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Risperdal Consta

Drug Overview: Risperdal Consta

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Risperdal Consta (Johnson&Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin ...

  • Industries : Mental Health, Pathology
  • Countries : United States, European Union, Japan
Bipolar Disorder Disease Coverage to 2024

Bipolar Disorder Disease Coverage to 2024

  • $ 22000
  • Industry report
  • April 2018

Disease Overview Bipolar disorder is a psychiatric disorder characterized by unusual shifts in mood, energy, activity levels, and the ability to carry out everyday tasks. Patients with the disorder may ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, Japan, European Union
Seroquel/Seroquel XR

Seroquel/Seroquel XR

  • $ 10000
  • Industry report
  • April 2018

Drug Overview The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Geodon

Drug Overview: Geodon

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer. Geodon initially launched in the US in 2001 for the treatment of schizophrenia. ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : Japan, United States
Drug Overview: Latuda

Drug Overview: Latuda

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By ...

  • Industries : Mental Health, Pathology
  • Countries : United Kingdom, Italy, Japan, European Union, United States, Germany, Spain
Drug Overview: Rexulti

Drug Overview: Rexulti

  • $ 10000
  • Industry report
  • April 2018

Drug Overview Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Invega Sustenna/Invega Trinza

Drug Overview: Invega Sustenna/Invega Trinza

  • $ 10000
  • Industry report
  • March 2018

Drug Overview Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson&Johnson) are long-acting injectable formulations developed by Johnson&Johnson, using with Alkermes’s technology. The ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : United States, European Union, Japan
Schizophrenia Disease Coverage to 2024

Schizophrenia Disease Coverage to 2024

  • $ 22000
  • Industry report
  • March 2018

Schizophrenia is a serious mental illness, characterized by incoherent or illogical thoughts, bizarre behavior and speech, and delusions or hallucinations, such as hearing voices. Schizophrenia typically ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, European Union
Drug Overview: Lonasen

Drug Overview: Lonasen

  • $ 10000
  • Industry report
  • March 2018

Drug Overview Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist. The drug possesses a stronger blocking action to D2 receptors than to ...

  • Industries : Mental Health, Pathology, Therapy
  • Countries : Japan
Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Industry

  • $ 5450
  • Industry report
  • January 2018

This report analyzes the worldwide markets for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics in US$ Million.The report provides separate comprehensive analytics for the US, Canada, Japan, ...

  • Industries : Mental Health, Therapy, Pathology
  • Countries : United States, World, APAC, Japan
Multiple Sclerosis Forecast and Market Analysis to 2025

Multiple Sclerosis Forecast and Market Analysis to 2025

  • $ 22000
  • Industry report
  • November 2017

DISEASE OVERVIEWMultiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Industries : Mental Health, Pathology
  • Countries : European Union, United States, Japan
Drug Analysis: Copaxone

Drug Analysis: Copaxone

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewCopaxone is an immunomodulator composed of four amino acids found in myelin basic protein, believed to act by modifying immune processes in the pathogenesis of MS. It was the third disease-modifying ...

  • Industries : Mental Health
  • Countries : United States, Japan, European Union
Drug Anaylsis: Gilenya

Drug Anaylsis: Gilenya

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewGilenya is a synthetic derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb isaria sinclarii which acts as a potent agonist at four of the S1P receptors (S1P1, S1P3, S1P4, ...

  • Industries : Mental Health
  • Countries : United States, Japan, European Union
Drug Analysis: Siponimod

Drug Analysis: Siponimod

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewSiponimod (Novartis) is a sphingosine-1-phosphate (S1P) agonist with selectivity for the S1P1 and S1P5 receptor subtypes. It is Novartis’s follow-on product to Gilenya (fingolimod; Nova ...

  • Industries : Mental Health
  • Countries : United States, Japan, European Union
Drug Analysis: Betaseron

Drug Analysis: Betaseron

  • $ 10000
  • Industry report
  • November 2017

Drug OverviewBetaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon). ...

  • Industries : Mental Health
  • Countries : United States, European Union, Japan
EpiCast Report: Epilepsy - Epidemiology Forecast to 2026

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • October 2017

EpiCast Report: Epilepsy - Epidemiology Forecast to 2026SummaryEpilepsy is a brain disorder characterized by recurrent and unpredictable seizures that are caused by sudden, disorderly, and excessive neuronal ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, France, World
EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026

  • $ 3995
  • Industry report
  • October 2017

EpiCast Report: Alzheimer’s Disease - Epidemiology Forecast to 2026SummaryAlzheimer’s disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly, characterized ...

  • Industries : Mental Health, Pathology
  • Countries : United States, World, Spain, Japan, Italy, Germany, France, United Kingdom
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • October 2017

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2026SummaryEpilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. Seizures result from abnormal ...

  • Industries : Mental Health, Pathology
  • Countries : United States, Japan, North America, East Asia

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on